Modern approaches to the management of patients with osteoarthritis in real clinical practice
https://doi.org/10.30629/0023-2149-2023-101-2-3-141-146
Abstract
Osteoarthritis (OA) is a heterogeneous condition, which is based on low-intensity infl ammation that aff ects all tissues of the joint, and allows it to be considered as an organ pathology, that is, a disease of the whole organ — the joint. The article presents algorithms for managing a patient with OA, including non-drug, pharmacological treatment and surgical interventions. Drug treatment consists of three stages of sequential prescription of medications. The early use of symptomatic slow-acting drugs in osteoarthritis (SYSADOA) is emphasized. It increases the eff ectiveness of treatment, reduces pain, improves joint function, and thereby improves the quality of life of patients.
About the Authors
A. M. LilaRussian Federation
Lila Alexander M.
115522, Moscow
125993, Moscow
L. I. Alekseeva
Russian Federation
Alekseeva Lyudmila I.
115522, Moscow
125993, Moscow
References
1. Sellam J., Berenbaum F. The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat. Rev. Rheumatol. 2010;6:625–635.
2. Hasegawa A., Otsuki S., Pauli C. et al. Anterior cruciate ligament changes in the human knee joint in aging and osteoarthritis. Arthritis Rheum. 2012;64:696–704.
3. Burr D.B., Gallant M.A. Bone remodelling in osteoarthritis. Nat. Rev. Rheumatol. 2012;8:665–673.
4. Neogi T. Clinical signifi cance of bone changes in osteoarthritis. Ther. Adv. Musculoskelet. Dis. 2012;4:259–267.
5. Bijlsma J., Berenbaum F., Lafeber P. Osteoarthritis: an update with relevance for clinicaдpractice. Lancet. 2011;377(9783):2115–26. DOI: 10.1016/S0140-6736(11)60243-2
6. Kashevarova N.G., Alekseeva L.I., Anikin S.G., Demin N.V., Smirnov A.V., Nasonov E.L. Osteoarthritis of the knee joints: risk factors for the progression of joint disease in a fi ve-year prospective disease. Proceedings of the III Eurasian Congress of Rheumatologists (Minsk, Republic of Belarus, May 26–27, 2016). Issues of organization and informatization of health care. Analytical Information Bulletin. 2016:44–149. (In Russian)].
7. Bruyère O., Cooper C., Pelletier J.-P., Branko J., Brandy M.L. et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Seminars in Arthritis and Rheumatism. 2014:2–11.
8. Greenen R., Overman C., Christensen R. et al. EULAR recommendations for the health professionals’ approach to pain management in infl ammatory arthritis and osteoarthritis. Ann. Rheum. Dis. 2018;77:797–807. DOI: 10.1136/annrheumdis-2017-212662
9. Hochberg M.C., Martel-Pelletier J., Monfort J. et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann. Rheum. Dis. 2016;75:37–44.
10. Pelletier J., Raynauld J., Paiement P., Dorais M., Martel-Pelletier J. In an International, Multicentre, Double-blind, Randomised Study in Knee Osteoarthritis Patients, Diacerein Was Found as Eff ective as Celecoxib in Reducing Pain and Disease Symptoms [abstract]. Arthritis Rheumatol. 2019;71(10). ACR 2019.
11. Lee Y.H. Chondroitin sulfate is superior to placebo in symptomatic kneeosteoarthritis. Ann. Rheum. Dis. 2018;77(8):e54. DOI: 10.1136/annrheumdis-2017-212452.
12. Zhu X., Wu D., San L., Wan Y., She Y., Zhuan X. et al. Comparative eff ectiveness of glucosamine, chondroitin, acetaminophen or celecoxib for the treatment of knee and/or hip osteoarthritis: a network metaanalysis. Clinical and Experimental Rheumatology. 2018;36:595–602.
13. Yang W., Sun C., He S.Q. et al. The Effi cacy and Safety of DiseaseModifying Osteoarthritis Drugs for Knee andHip Osteoarthritis – a Systematic Review and Network Meta-Analysis. J. Gen. Intern. Med. 2021;36(7):2085–2093. DOI: 10.1007/s11606-021-06755-z
14. Honvo G., Reginster J.-Y., Rabenda V., Geerinck A., Mkinsi O., Charles A. et al. Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(1). DOI: 10.1007/s4026 6-019-00662-z
15. Conaghan P.G., Arden N., Avouac B., Migliore A., Rizzoli R. Safety of paracetamol: what does the literature say? Drugs Aging. 2019;36(1). DOI: 10.1007/s40266-019-00658-9
16. Wolff D.G., Christophersen C., Brown S.M., Mulcahey M.K. Topical nonsteroidal anti-infl ammatory drugs in the treatment of knee ost eoarthritis: a systematic review and meta-analysis. Phys. Sportsmed. 2021;49(4):381–391. DOI: 10.1080/00913847.2021.1886573
17. Coxib and traditional NSAID Trialists’ (CNT) Collaboration: Bhala N., Emberson J., Merhi A., Abramson S., Arber N. et al. Vascular and upper gastrointestinal eff ects of non-steroidal antiinfl ammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–79.
18. Karateev A.E., Nasonov E.L., Ivashkin V.T., Martynov A.I., Yakhno N.N., Arutyunov G.P. et al. Rational use of non-steroid anti-infl ammatory drugs. Clinical recommendations. Scientifi c and practical rheumatology. 2018;56:1–29. (In Russian)]. DOI: 10.14412/1995-4484-2018-1-29
19. Honvo G., Reginster J.Y., Rannou F., Rygaert X., Geerinck A., Rabenda V. et al. Safety of intra-articular hyaluronic acid injections in osteoarthritis: outcomes of a systematic review and metaanalysis. Drugs Aging. 2019;36(1). DOI: 10.1007/s40266-019-00657-w
20. Fuggle N., Curtis E., Shaw S., Spooner L., Bruyere O., Ntani G. et al. Safety of opioids in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(1). DOI: 10.1007/s40266-019-00666-9
Review
For citations:
Lila A.M., Alekseeva L.I. Modern approaches to the management of patients with osteoarthritis in real clinical practice. Clinical Medicine (Russian Journal). 2023;101(2-3):141-146. (In Russ.) https://doi.org/10.30629/0023-2149-2023-101-2-3-141-146